Pharmakina grows cinchona trees, extracts quinine (the active pharmaceutical ingredient), and manufactures finished antimalarial medicines, all from their base in Bukavu, DRC. This vertical integration means the entire supply chain stays local. Jobs are created at every stage of production, from plantation workers and agronomists to lab technicians and factory operators. It also means that when global supply chains fail, Pharmakina keeps producing affordable, essential medicine for the region.

The company partners with over 2,500 smallholder farmers through sustainable agriculture programs, providing disease-resistant seedlings, training, and ongoing support. Talanton's investment will help grow that farmer network to over 5,500 while doubling API extraction capacity. Pharmakina hit 82% of its 2025 production targets by mid-year, domestic sales grew 24% over the prior year, and export revenue jumped 123%.

Malaria killed 610,000 people in 2024. Ninety-five percent of those deaths occurred in sub-Saharan Africa. Seventy-six percent were children under five. Pharmakina is one of only a few companies in the world producing quinine at scale and the only one doing it on the African continent.

Every treatment course they manufacture is one less dependency on imported medicine, one more step toward pharmaceutical self-sufficiency in the region that needs it most.